​Infectious disease and microbiology – Mucormycosis


Mucormycosis is a life-threatening opportunistic fungal infection characterized by vascular invasion, thrombosis, and extensive tissue necrosis. It primarily affects immunocompromised individuals, particularly those with uncontrolled diabetes or hematologic malignancies.


The disease is relatively rare, with an estimated incidence of 1.7 cases per million people annually in the United States, but it carries a very high mortality rate. It occurs worldwide and is increasingly recognized in patients receiving antifungal prophylaxis that does not cover Mucorales (e.g., voriconazole).


Major risk factors include uncontrolled diabetes mellitus (especially with ketoacidosis), hematologic malignancies, organ transplantation, prolonged neutropenia, chronic steroid use, deferoxamine therapy, burns, trauma, and intravenous drug use. HIV infection and malnutrition also predispose to disease. Nosocomial outbreaks have been reported, particularly due to contaminated dressings.


Infection occurs through inhalation, ingestion, or direct inoculation of fungal spores. Once inside the host, Mucorales organisms invade blood vessels, leading to thrombosis, infarction, and necrosis, with rapid spread to adjacent tissues and possible hematogenous dissemination.


The most common causative organisms are molds from the order Mucorales, including Rhizopus, Mucor, Rhizomucor, Absidia, Cunninghamella, and Saksenaea. These fungi are ubiquitous in the environment, especially in soil and decaying organic matter.


Clinical presentation varies depending on the site of infection but is typically rapidly progressive and severe.


Rhinocerebral (craniofacial) mucormycosis, most common in diabetics, begins in the sinuses and spreads to the orbit and brain. Patients may present with facial pain, nasal congestion, black necrotic lesions on the palate or nasal mucosa, orbital swelling, vision loss, and altered mental status.


Pulmonary mucormycosis occurs mainly in neutropenic patients and presents with fever, progressive lung infiltrates, and poor response to antibiotics.


Gastrointestinal mucormycosis is more common in malnourished children and presents with abdominal pain, bleeding, or perforation.


Cutaneous mucormycosis occurs after trauma or burns and presents with necrotic ulcers, eschars, and tissue destruction.


Disseminated disease may involve the brain, liver, spleen, or heart and carries a very poor prognosis.


Diagnosis relies on early clinical suspicion and histopathological confirmation. Microscopy shows broad, nonseptate, irregularly branching hyphae. Culture may be performed from tissue samples, and imaging (CT or MRI) helps assess the extent of disease. Unlike other fungal infections, β-D-glucan tests are not useful.


Treatment requires urgent, aggressive management.


First-line therapy includes intravenous amphotericin B (liposomal formulation preferred due to lower toxicity).


Second-line or salvage therapy includes posaconazole, sometimes used in combination regimens.


Equally important are reversal of underlying risk factors (e.g., control of diabetes, reduction of immunosuppression) and prompt surgical debridement of necrotic tissue, which is often lifesaving.


Additional supportive therapies may include granulocyte transfusions, growth factors, hyperbaric oxygen therapy, and iron chelation strategies in selected cases.


The prognosis remains poor, especially if diagnosis is delayed. Untreated rhinocerebral disease is almost universally fatal within days, while even with treatment, survival in diabetic patients is approximately 50%. Outcomes are worse in immunocompromised individuals and in disseminated disease.


Complications include vascular thrombosis, brain abscesses, pulmonary dissemination, bowel infarction, hemorrhage, and widespread tissue destruction, often leading to death if not rapidly treated.

Infectious disease and microbiology – Mycotic aneurysms
Mycotic aneurysms are infected aneurysms of blood vessels that arise as part of an infectious process, most commonly infective endocarditis (IE). Despite the name, “mycotic” refers to the fungus-like shape of the aneurysm, not the cause, which is usually bacterial.

These aneurysms may be intracranial or extracranial, and they can also occur due to infection of a preexisting aneurysm or arterial wall (microbial arteritis).

Epidemiologically, about 2–4% of patients with infective endocarditis develop intracranial mycotic aneurysms, although the true incidence is likely underestimated due to asymptomatic cases. The prevalence in the general population is unknown but has decreased in the antibiotic era.

Major risk factors include:

• Infective endocarditis
• Intravenous drug use
• Arterial trauma
• Contiguous infections near blood vessels
• Immunosuppression and advanced age

The pathophysiology involves infection and weakening of the arterial wall through several mechanisms:

• Septic emboli from cardiac vegetations lodging in vessels
• Bacteremic seeding of damaged arterial intima
• Direct spread from nearby infections
• Direct inoculation from trauma or procedures

The most common causative organism is Staphylococcus aureus (up to 70%), followed by Salmonella species. Other pathogens include streptococci, gram-negative bacteria, Mycobacterium tuberculosis, and fungi such as Candida and Aspergillus.

Clinically, many patients are asymptomatic until complications occur.
Symptoms depend on location:

• Intracranial aneurysms: headache, fever, stroke-like symptoms, seizures
• Aortic aneurysms: abdominal or back pain, fever
• Rupture: sudden deterioration, bleeding, shock

Physical findings may include neurologic deficits, meningeal signs, abdominal tenderness, or signs of hemorrhage, depending on the site.

Diagnosis relies on a combination of laboratory tests and imaging.

• Blood cultures are positive in 50–85% of cases
• Elevated white blood cell count and anemia are common
• Conventional angiography is the gold standard
• CT, MRI, and Doppler ultrasound help localize and assess the aneurysm

Pathologically, there is destruction of the arterial wall, inflammation, and eventual dilation with risk of rupture, especially at vessel branching points.

Treatment involves prolonged intravenous antibiotics (at least 6–8 weeks) tailored to the identified organism.
Some patients, especially those with intracranial aneurysms, may improve with antibiotics alone.

Surgical or endovascular intervention is required in cases of:

• Rupture or bleeding
• Enlarging aneurysm despite therapy
• High-risk anatomical locations

Close monitoring is essential, particularly during the first weeks of treatment, as rupture risk is highest early but may still occur months later.

The prognosis is serious, with mortality depending on rupture status:

• ~30% mortality if aneurysm is intact
• Up to 80% mortality if rupture occurs

Complications include:

• Hemorrhage (e.g., subarachnoid hemorrhage)
• Embolization
• Vascular insufficiency
• Shock and death
• ​

Early recognition and treatment of underlying infections, especially infective endocarditis, are critical to improving outcomes.

Infectious disease and microbiology – Myocarditis
Myocarditis is an inflammatory condition of the heart muscle (myocardium) that can result from a wide range of infectious agents, immune-mediated mechanisms, or external toxins. It may occur due to direct infection of cardiac tissue or from an immune response in which antibodies cross-react with myocardial cells, leading to damage. Although relatively uncommon, with an estimated incidence of 1–10 cases per 100,000 individuals, myocarditis is clinically significant because it contributes to up to 12% of sudden cardiac deaths in adolescents and young adults, affecting young males. Its true prevalence is difficult to determine because presentations range from mild, self-limited illness to severe heart failure or sudden death.


The disease is associated with numerous infectious causes, most commonly viral pathogens such as enteroviruses (especially Coxsackie B), adenovirus, influenza, cytomegalovirus, Epstein-Barr virus, HIV, and others. Bacterial, rickettsial, spirochetal, fungal, protozoal, and parasitic infections may also lead to myocarditis. Notably, Trypanosoma cruzi (Chagas disease) and HIV are important contributors in certain populations. Noninfectious triggers such as toxins, drugs, and systemic inflammatory diseases can also play a role. Immunocompromised individuals are at increased risk, and vaccination against viral pathogens may help reduce incidence.

Pathophysiologically, myocardial injury results from a combination of direct cytotoxic effects of pathogens, immune-mediated inflammation, cytokine release (e.g., tumor necrosis factor-alpha), and apoptosis of cardiac cells, all of which impair cardiac function.
​
Clinically, patients often report a recent viral-like illness with fever, malaise, or respiratory symptoms, followed by chest pain, palpitations, shortness of breath, or syncope. In some cases, myocarditis mimics acute myocardial infarction, while in others it presents later as chronic heart failure. Physical examination may reveal tachycardia, arrhythmias, signs of heart failure, or an S3 gallop, along with systemic features depending on the underlying cause.
​
Diagnosis involves a combination of laboratory testing, imaging, and sometimes biopsy. Laboratory findings may include leukocytosis, elevated inflammatory markers, and increased cardiac enzymes such as troponin. Imaging studies—especially echocardiography and cardiac MRI—help assess cardiac function and inflammation. Electrocardiography often shows nonspecific changes or conduction abnormalities. The gold standard for diagnosis is endomyocardial biopsy, which demonstrates inflammatory infiltration and myocardial necrosis, although it carries procedural risks and may yield false negatives.

Management is largely supportive, focusing on treatment of heart failure with medications such as diuretics, ACE inhibitors, and beta-blockers. Specific antimicrobial or antiviral therapy is used when an identifiable cause is present. In severe cases, advanced supportive measures such as ventricular assist devices or extracorporeal membrane oxygenation may be required, and cardiac transplantation may be considered in refractory cases. Adjunctive therapies such as intravenous immunoglobulin or immunosuppressive agents may be used selectively.

Follow-up care includes gradual rehabilitation, serial cardiac monitoring, and repeat imaging, with restrictions on physical activity during recovery. Long-term outcomes vary: some patients recover completely, while others develop complications such as dilated cardiomyopathy, arrhythmias, heart block, or cardiogenic shock. Early recognition and appropriate management are essential to improve prognosis and reduce the risk of serious complications, including sudden cardiac death.

​

Infectious disease and microbiology – Myelitis
Myelitis is an inflammatory condition of the spinal cord caused by infection or involvement of adjacent tissues, leading to neurologic dysfunction affecting motor, sensory, and autonomic systems.
The epidemiology varies widely depending on the underlying infectious cause. It can occur in both immunocompetent and immunocompromised individuals, although the latter are at higher risk.
Risk Factors

• Immunocompromised state (e.g., HIV, malignancy, steroid use)

Prevention

• Vaccination against poliomyelitis and varicella-zoster virus (VZV)

Pathophysiology
Inflammation may involve:

• Entire cross-section of the spinal cord → transverse myelitis
• Focal segments → localized myelitis
• Nerve roots involvement → radiculomyelitis

This inflammation leads to demyelination, neuronal injury, and impaired nerve conduction, resulting in neurologic deficits.
Etiology
A wide range of infectious agents can cause myelitis:
Viral causes (most common):

• Herpes viruses (HSV, EBV, VZV, CMV, HHV-6)
• HIV (vacuolar myelopathy)
• HTLV-1 (tropical spastic paraparesis)
• Influenza virus
• Enteroviruses (coxsackie, echovirus, enterovirus 70/71)
• West Nile virus

Bacterial and other causes:

• Mycoplasma pneumoniae
• Lyme disease (Borrelia burgdorferi)
• Syphilis (posterior column involvement – tabes dorsalis)
• Tuberculosis (spondylitis, tuberculomas)
• Leptospirosis

Fungal and parasitic causes:

• Aspergillus, Coccidioides, Blastomyces
• Schistosomiasis
• Neurocysticercosis

Other mechanisms:

• Epidural abscess causing spinal cord compression

Clinical Presentation
History:

• Rapid onset (hours to days)
• Motor weakness (often bilateral)
• Sensory disturbances
• Bladder and bowel dysfunction
• Back pain or radicular (dermatomal) pain

Physical Examination:
Transverse Myelitis:

• Sensory level on the trunk
• Loss of motor and sensory function below lesion
• Reflexes initially decreased, later hyperactive

Poliomyelitis:

• Asymmetric weakness
• Fasciculations and muscle atrophy
• Loss of reflexes (lower motor neuron signs)

Zoster Myelitis:

• Dermatomal pain and sensory loss
• Ipsilateral to rash
• Motor involvement is less common

Diagnosis
Laboratory Tests:

• CSF analysis:
  • Cell count, glucose, protein
  • PCR for HSV, CMV, VZV
  • West Nile virus IgM
  • VDRL (for syphilis)
• Serology for HIV, Lyme disease, enteroviruses

Typical findings:

• Normal glucose (viral causes)
• Elevated protein
• Lymphocytic predominance (except early herpes infections)

Imaging:

• MRI of the spine shows focal or diffuse enhancing lesions

Pathology:

• Inflammatory infiltration (lymphocytes, monocytes)
• Demyelination and axonal injury

Differential Diagnosis
Noninfectious causes include:

• Multiple sclerosis
• Vitamin B12 deficiency
• Autoimmune diseases (e.g., SLE)
• Neurosarcoidosis
• Paraneoplastic syndromes

Treatment
Targeted antimicrobial therapy based on cause:

• HSV → Acyclovir
• CMV → Ganciclovir or foscarnet
• HIV → Antiretroviral therapy
• Other infections → Etiology-specific treatment

Adjunctive therapy:

• Corticosteroids (e.g., IV methylprednisolone) are often used, though their benefit remains uncertain

Surgical management:

• Emergency decompression if spinal cord compression (e.g., epidural abscess) is present

Follow-Up and Prognosis

• Patients often require rehabilitation and neurologic follow-up
• Relapses may occur depending on etiology

Complications

• Chronic neuropathic pain
• Partial or complete paralysis

Early recognition and treatment are critical to prevent permanent neurologic damage.

​

Infectious disease and microbiology – Nocardiosis
Nocardiosis is an invasive opportunistic infection caused by Nocardia species, a group of aerobic, Gram-positive, branching filamentous bacteria belonging to the order Actinomycetales. First described in 1889, the disease may present as localized or disseminated infection, most commonly involving the lungs, but it can spread hematogenously—especially to the central nervous system (CNS)—and virtually any organ, including the skin, heart, kidneys, bones, and soft tissues.

Clinical manifestations range from pulmonary disease (acute, chronic, or subclinical) to brain abscesses, cellulitis, lymphocutaneous disease, actinomycetoma, and keratitis.

The infection is typically acquired through inhalation of organisms from soil or organic matter, making the lungs the primary site of infection, although traumatic skin inoculation or mucosal entry can also occur. There is no significant person-to-person transmission. Approximately 1,000 cases occur annually in the United States, with most involving pulmonary or systemic disease. Although nocardiosis can affect individuals of any age, it is more common in adults and males, and while many patients are immunocompromised, up to one-third are immunocompetent.

Major risk factors include conditions that impair cell-mediated immunity, such as HIV/AIDS, malignancy, organ transplantation, corticosteroid or TNF-alpha inhibitor therapy, Cushing’s syndrome, and chronic granulomatous disease. The most common pathogen is Nocardia asteroides, though other species like N. brasiliensis are associated with cutaneous disease, particularly in tropical regions.

Clinically, nocardiosis presents with nonspecific symptoms, especially in pulmonary disease, including productive cough, fever, weight loss, malaise, and occasionally dyspnea or hemoptysis. The disease may follow a chronic or relapsing course, and dissemination—particularly to the brain—may initially be asymptomatic. Cutaneous forms present as cellulitis, nodules, ulcers, or lymphocutaneous spread, while actinomycetoma causes chronic, deforming lesions with draining sinuses. CNS involvement typically manifests as brain abscesses, which are often multiple and indolent.

Diagnosis relies on microscopic and microbiological identification. Specimens such as sputum or pus reveal branching, beaded Gram-positive filaments, often requiring modified acid-fast staining. Cultures grow slowly and may take up to several weeks, forming chalky, pigmented colonies with a characteristic odor. Imaging studies such as chest X-ray or CT may show nodules, cavitations, or infiltrates, while brain imaging (CT/MRI) is essential when CNS involvement is suspected.

Treatment is prolonged and often requires combination antimicrobial therapy. First-line treatment includes trimethoprim-sulfamethoxazole (TMP-SMX), with alternatives such as amikacin, imipenem, ceftriaxone, or minocycline, depending on disease severity and susceptibility patterns. Therapy duration is typically 6–12 months, longer for CNS or immunocompromised cases. Surgical drainage or excision may be necessary for large abscesses or extensive disease.
​
Close follow-up is essential due to the risk of relapse or dissemination, even after apparent clinical improvement. Prognosis depends on immune status and extent of disease; mortality is relatively low in immunocompetent patients with localized pulmonary disease (~15%) but significantly higher in disseminated or CNS infections. Complications include brain abscess rupture, spinal cord compression, empyema, fistula formation, and widespread organ involvement, highlighting the need for early diagnosis and aggressive management.

​

Infectious disease and microbiology – Neuropathies, infectious


Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.


The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.


Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.


Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.


Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.


Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.

Infectious disease and microbiology – Necrotizing soft-tissue infections
Necrotizing soft-tissue infections (NSTIs) are rapidly progressive, life-threatening infections that involve the fascia and may extend to muscles, leading to extensive tissue destruction. They usually arise after a break in the skin, such as trauma, surgery, or even minor events like insect bites, although in many cases no clear initiating factor is identified. Clinically, they may present as necrotizing cellulitis, necrotizing fasciitis, or pyomyositis, and they are associated with high mortality rates exceeding 20%, often reaching around one-third of cases.

The incidence of NSTIs has been increasing, and although still uncommon, most clinicians will encounter at least one case during their practice. Risk factors include immunocompromised states, particularly diabetes mellitus and peripheral vascular disease, as well as obesity, chronic liver or renal disease, HIV infection, intravenous drug use, older age, and frequent hospitalizations. Certain populations, such as athletes or institutionalized individuals, are more prone to infections caused by community-associated MRSA.

Pathophysiologically, bacteria invade subcutaneous tissues and spread rapidly along fascial planes. The production of toxins and enzymes leads to local ischemia, impaired immune response, and widespread necrosis, allowing the infection to advance quickly. Most cases are polymicrobial (Type 1), involving a mixture of aerobic and anaerobic organisms, while others are monomicrobial (Types 2 and 3), commonly caused by Group A Streptococcus, Staphylococcus aureus, or Clostridium species.

Clinically, early symptoms may appear deceptively mild, with pain, erythema, swelling, and tachycardia, but the hallmark is pain out of proportion to physical findings. As the disease progresses, patients develop skin discoloration, bullae, crepitus, anesthesia, and systemic signs such as fever, hypotension, and shock, often rapidly progressing to sepsis and multi-organ failure. Diagnosis is primarily clinical, and urgent surgical exploration remains the gold standard, as delays can be fatal. Laboratory findings and scoring systems such as the LRINEC score may support suspicion, while imaging (CT or MRI) can reveal fascial thickening or gas in tissues but should not delay treatment.

Management requires immediate and aggressive intervention, combining broad-spectrum intravenous antibiotics with early surgical debridement, which is the most critical factor in reducing mortality. Empiric antibiotic therapy should cover gram-positive, gram-negative, and anaerobic organisms, with adjustments based on culture results. Repeated surgical exploration is often necessary, and in severe cases, amputation may be required. Patients typically require intensive care support, including fluid resuscitation, hemodynamic stabilization, and nutritional support.
​
Despite advances in management, prognosis remains serious. Mortality has improved with early recognition and aggressive treatment but remains high, and survivors often face significant morbidity. Complications include sepsis, acute respiratory distress syndrome, renal failure, nosocomial infections, and limb loss, highlighting the importance of prompt diagnosis and multidisciplinary management.

​

Ophthalmology – Dry Eye Syndrome (Keratoconjunctivitis Sicca)
Dry eye syndrome is a multifactorial disease of the ocular surface characterized by an unstable or insufficient tear film, leading to discomfort, visual disturbance, and potential damage to the cornea and conjunctiva. It is broadly classified into three main types: aqueous tear-deficient, evaporative, and exposure-related dry eye. The condition may occur as an isolated ocular disorder or as part of systemic diseases such as autoimmune conditions.

This is a very common condition, particularly in older adults and females. Prevalence increases with age, affecting up to 19% of individuals over 80 years. Risk factors include aging, female sex, ocular surgeries (such as LASIK or cataract surgery), diabetes, and contact lens use. Environmental factors like low humidity and prolonged screen use also contribute significantly.

The pathophysiology involves tear film instability and ocular surface desiccation, which leads to inflammation, loss of goblet cells, and epithelial damage. Over time, this can result in keratinization and chronic surface changes. In aqueous deficiency, there is reduced tear production, whereas evaporative dry eye is usually due to meibomian gland dysfunction, causing rapid tear evaporation. Exposure-related dry eye results from incomplete eyelid closure or reduced blinking.

Patients commonly report burning, itching, gritty sensation, foreign body sensation, and intermittent blurred vision, especially with prolonged visual tasks like reading or computer use. Symptoms often worsen in dry, windy, or air-conditioned environments and improve in humid conditions. Some patients paradoxically experience excess tearing, which is a reflex response to irritation.

On examination, findings may include conjunctival redness, reduced tear meniscus, and superficial punctate keratitis in exposed areas of the cornea. In evaporative dry eye, signs of meibomian gland dysfunction such as thickened secretions, lid margin inflammation, and foamy tear film may be present. Severe cases may show filamentary keratitis or epithelial defects.

Diagnosis is supported by clinical tests. The Schirmer test measures tear production, with low values indicating aqueous deficiency. The tear breakup time (TBUT) assesses tear film stability, with values less than 10 seconds suggesting evaporative dry eye. Rose Bengal staining highlights damaged or devitalized epithelial cells and helps assess severity.

Management is stepwise and depends on severity and type. First-line treatment includes artificial tears, gels, and ointments to supplement and preserve moisture. Environmental modifications such as using humidifiers and avoiding irritants are also important. For evaporative causes, warm compresses and lid hygiene are essential, and oral doxycycline or omega-3 supplements may be beneficial.

Second-line therapies include topical cyclosporine, autologous serum eye drops, and systemic secretagogues such as pilocarpine or cevimeline in selected cases. In more severe disease, procedures such as punctal plugs or punctal occlusion help retain tears. For exposure-related cases, interventions like lid taping, moisture chambers, or surgical options (e.g., tarsorrhaphy) may be required.

Patients should be advised to stay hydrated, blink frequently during screen use, and avoid dry environments. Referral to a specialist is indicated if systemic conditions like Sjögren’s syndrome are suspected.
​
The prognosis is generally excellent, with most patients achieving good symptom control with appropriate therapy. However, untreated or severe cases can lead to complications such as filamentary keratitis, corneal ulceration, or rarely corneal perforation, highlighting the importance of early recognition and management.

​

Ophthalmology – Down Syndrome (Trisomy 21)
Down syndrome, also known as Trisomy 21, is a chromosomal disorder caused by the presence of an extra copy of chromosome 21. It was first described by John Langdon Down in 1866. The condition affects individuals worldwide across all ethnic and socioeconomic groups and is one of the most common genetic causes of intellectual disability.

The incidence is approximately 1 in 733 live births in the United States, with risk strongly associated with advanced maternal age. For example, the risk increases significantly from about 1 in 1,562 in women aged 20–24 to about 1 in 19 in women over 45. Increased paternal age has also been identified as a contributing risk factor. Most cases result from meiotic nondisjunction, leading to a full extra chromosome, although partial or mosaic forms may also occur.

Clinically, Down syndrome presents with a characteristic set of physical features. These include a round face, small chin (microgenia), macroglossia (large tongue), and short neck. Ocular findings are particularly relevant in ophthalmology and include epicanthal folds, upward slanting palpebral fissures, and Brushfield spots—small whitish or grayish speckles seen at the periphery of the iris. Patients often also have strabismus, cataracts, and other visual abnormalities. General features include hypotonia, short stature, single palmar crease, and varying degrees of intellectual disability and speech delay.

Down syndrome is associated with multiple systemic conditions. These include thyroid disorders, gastrointestinal anomalies, hematologic malignancies, and an increased risk of early-onset Alzheimer’s disease, often developing before age 50. Fertility is typically reduced, especially in males.

Diagnosis can be made prenatally through screening and diagnostic techniques such as amniocentesis, chorionic villus sampling, or umbilical cord blood sampling. Postnatally, diagnosis is confirmed by karyotype analysis. Ophthalmic evaluation may include imaging such as optical coherence tomography (OCT), which can demonstrate macular hypoplasia, and visual electrophysiologic testing.

There is no cure for Down syndrome, so management focuses on supportive care and treatment of associated conditions. Early intervention programs, including speech therapy, occupational therapy, and educational support, significantly improve developmental outcomes. Ophthalmic issues such as strabismus or cataracts should be managed appropriately to optimize visual function.
​
Follow-up care is lifelong and multidisciplinary. With advances in medical care and supportive services, life expectancy has improved significantly, increasing from approximately 25 years in 1980 to nearly 50 years or more today. Many individuals now live into adulthood with improved quality of life, although neurodegenerative complications remain a concern later in life.

​